Matrix metalloproteinase-2 and -9 and tissue inhibitor of metalloproteinase-1 and -2 in sera and urine of patients with renal carcinoma

Oncology Letters

Volumn 7, Issue 3, 2014, Pages 621-626

  Di Carlo, Angelina ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Kidney carcinoma; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Sera; Tissue inhibitor of metalloproteinase 1; Tissue inhibitor of metalloproteinase 2; Urine

Indexed keywords

GELATINASE A; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; MIDDLE AGED; URINALYSIS;

EID: 84893008392     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1755     Document Type: Article

References (20)

1. Jemal A, Siegel R, Xu and Wrad E: Cancer statistics, 2010. Ca Cancer J Clin 60: 277-300, 2010.
2. Cohen HT and McGoven FJ: Renal-cell carcinoma. N Engl J Med 353: 2477-2490, 2005.
3. Nagase H and Woessner JF Jr: Matrix metalloproteinases. J Biol Chem 274: 21491-21494, 1999.
4. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
5. Björklund M and Koivunen E: Gelatinase-mediated migration and invasion of cancer cell. Biochim Biophys Acta 1755: 37-69, 2005.
6. Brew K, Dinakarpandian D and Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochem Biophys Acta 1477: 267-283, 2000.
7. Baker AH, Ahonen M and Kähäri VM: Potential applications of tissue inhibitor of metalloproteinase (TIMP) overexpression for cancer gene therapy. Adv Exp Med Biol 465: 469-483, 2000.
8. Hayakawa T, Yamashita K, Tanzawa K, Uchijima E and IwataK: Growth-promoting activity of tissue inhibitor of metalloproteinase-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 298: 29-32, 1992.
9. Visse R and Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases. Structure, functions and biochemistry. Cir Res 92: 827-839, 2003.
10. Stetler-Stevenson WG: Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase independent biological activities. Sci Signal 1: re6, 2008.
11. Sobin LH and Wittekind CH (eds). International Union Against Cancer (UICC) TNM classification of malignant tumors. 6thedition. Wiley-Liss, New York, NY, pp193-195, 2002.
12. Di Carlo A: Matrix metalloproteinase-2 and-9 in the sera and in the urine of human oncocytoma and renal cell carcinoma. Oncol Rep 28: 1051-1056, 2012.
13. Struckmann K, Mertz K, Steu S, Storz M, Staller P, KrekW, Schraml P and Moch H: pVHL co-ordinately regulates CXCR4/CXCL12 and MMP2/MMP9 expression in human clear-cell renal cell carcinoma. J Pathol 214: 464-471, 2008.
14. Kallakury BV, Karikehalli S, Haholu A, Sheehan CE, Azumi N and Ross JS: Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clin Cancer Res 7: 3113-3119, 2001.
15. Bhuvarahamurthy V, Kristiansen GO, Johannsen M, LoeningSA, Schnorr D, Jung K and Staack A: In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9 and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma. Oncol Rep 15: 1379-1384, 2006.
16. Kugler A, Hemmerlein B, Thelen P, Kallerhoff M, Radzun HJ and Ringert RH: Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. J Urol 160: 1914-1918, 1998.
17. Kamiya N, Kishimoto T, Suzuki H, Sekita N, Nagai Y, OosumiN, Kito H, Tochigi N, Shinbo M, Nemori R, Ichikawa T, IgarashiT, Ito H and Ishikura H: Increased in situ gelatinolytic activity in renal cell tumor tissues correlates with tumor size, grade and vessel invasion. Int J Cancer 106: 480-485, 2003.
18. Lein M, Jung K, Laube C, Hübner T, Winkelmann B, Stephan C, Hauptmann S, Rudolph B, Schnorr D and Loening SA: Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma. Int J Cancer85: 801-804, 2000.
19. Cannon GM Jr and Getzenberg RH: Urinary matrix metalloproteinases activity is not significantly altered in patients with renal cell carcinoma. Urology 67: 848-850, 2006.
20. Sherief MH, Low SS, Miura M, Kudo N, Novick A and WeimbsT: Matrix metalloproteinase activity in urine of patients with renal cell carcinoma leads to degradation of extracellular matrix proteins: possible use as a screening assay. J Urol 169: 1530-1534, 2003.